What is Zacks Research’s Estimate for Teleflex Q4 Earnings?

Teleflex Incorporated (NYSE:TFX) – Equities researchers at Zacks Research dropped their Q4 2024 earnings per share (EPS) estimates for Teleflex in a research report issued on Wednesday, January 8th. Zacks Research analyst R. Department now expects that the medical technology company will post earnings of $3.83 per share for the quarter, down from their previous forecast of $3.85. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex’s Q2 2025 earnings at $3.71 EPS, Q3 2025 earnings at $3.75 EPS, Q4 2025 earnings at $4.18 EPS, FY2025 earnings at $15.16 EPS, Q4 2026 earnings at $4.16 EPS and FY2026 earnings at $16.59 EPS.

TFX has been the topic of a number of other research reports. Truist Financial reduced their target price on Teleflex from $227.00 to $200.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Royal Bank of Canada decreased their price objective on Teleflex from $275.00 to $245.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Monday, December 16th. Mizuho decreased their price target on shares of Teleflex from $275.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. Finally, StockNews.com raised shares of Teleflex from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $252.50.

Teleflex Stock Performance

Teleflex stock opened at $177.87 on Friday. Teleflex has a fifty-two week low of $171.69 and a fifty-two week high of $256.85. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The stock has a market cap of $8.26 billion, a P/E ratio of 35.36, a price-to-earnings-growth ratio of 1.84 and a beta of 1.16. The firm’s fifty day moving average price is $187.06 and its 200-day moving average price is $216.52.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, October 31st. The medical technology company reported $3.49 EPS for the quarter, topping the consensus estimate of $3.38 by $0.11. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company had revenue of $764.40 million during the quarter, compared to analyst estimates of $768.68 million. During the same quarter in the previous year, the firm earned $3.64 earnings per share. Teleflex’s revenue was up 2.4% on a year-over-year basis.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 15th were issued a dividend of $0.34 per share. The ex-dividend date was Friday, November 15th. This represents a $1.36 dividend on an annualized basis and a yield of 0.76%. Teleflex’s dividend payout ratio is currently 27.04%.

Institutional Trading of Teleflex

A number of institutional investors have recently modified their holdings of TFX. First Hawaiian Bank increased its stake in shares of Teleflex by 12.8% during the fourth quarter. First Hawaiian Bank now owns 4,282 shares of the medical technology company’s stock valued at $762,000 after buying an additional 487 shares during the period. Fulton Bank N.A. raised its holdings in Teleflex by 16.2% in the 4th quarter. Fulton Bank N.A. now owns 1,428 shares of the medical technology company’s stock worth $254,000 after purchasing an additional 199 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Teleflex by 364.9% in the 4th quarter. GAMMA Investing LLC now owns 795 shares of the medical technology company’s stock worth $141,000 after purchasing an additional 624 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Teleflex by 14.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 155,158 shares of the medical technology company’s stock valued at $38,374,000 after purchasing an additional 19,466 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of Teleflex by 2.7% during the third quarter. Principal Financial Group Inc. now owns 80,409 shares of the medical technology company’s stock valued at $19,887,000 after buying an additional 2,086 shares during the period. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.